Ni2o

Ni2o operates at the intersection of neuroscience, biotechnology, and diagnostic technology. Its stated focus combines a neuro-analytics platform and KIWI, a minimally invasive brain implant intended to record neural activity and deliver electrical and optical signals, with the separate ni2o RapidTest product for rapid communicable-disease screening. Ni2o’s potential differentiation is the combination of implant-based neurotechnology, neuro-analytics, and a separate rapid-testing platform, alongside leadership experience associated with major technology organizations and universities. Its disclosed $1.3 million debt financing is modest relative to heavily funded brain-interface companies, suggesting a comparatively small and early-stage operating footprint.

Ni2o was founded in 2016 and appears to have pursued two distinct development tracks: neurotechnology through the KIWI implant and diagnostics through ni2o RapidTest. The first visible inflection point was the Oct 26, 2020 recognition of RapidTest as an XPRIZE Rapid Covid Testing Competition semi-finalist, providing external visibility for the diagnostic concept. A second milestone followed on Apr 27, 2021, when the company completed a $1.3 million debt-financing round. The Nov 29, 2021 partnership with Nurosene Health marked an effort to apply Ni2o’s brain-computer-interface technology to Alzheimer’s and ALS research. The company is listed as active with an estimated employee range of one to ten and one featured current employee, CTO Richard Wirt. This indicates a small, research-oriented organization rather than a visibly scaled commercial business. Future trajectory depends on evidence of prototype validation, clinical or regulatory progress, customer adoption, and renewed capital formation, none of which is publicly documented here.